BNT411
BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) [1].
Product Specifications
CAS Number
2296821-50-4
UNSPSC
12352005
Target
Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bnt411.html
Purity
99.01
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C)N(C1CCOCC1)CCCCN2C(CCOC)=NC3=C2C4=C(C=CC=C4)N=C3N
Molecular Formula
C24H33N5O3
Molecular Weight
439.55
References & Citations
[1]Ugur Sahin, et al. Tlr7 agonist and combinations for cancer treatment. WIPO. WO2023083868. 2023-05-19
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD127 / IL7R (Marker of T-Reg Cells) (IL7R/2751), CF405S conjugate, 0.1mg/mL
